Leptin and the central neural mechanisms of obesity hypertension

Drugs of Today

Volumn 38, Issue 12, 2002, Pages 807-817

  Rahmouni, Kamal ^a,b   Haynes, William G ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; HORMONE RECEPTOR STIMULATING AGENT; LEPTIN; LEPTIN RECEPTOR; MELANOCORTIN; MELANOCORTIN RECEPTOR; MELANOCORTIN RECEPTOR AGONIST; METHIONYLLEPTIN; NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ADIPOCYTE; ADRENAL GLAND; ADRENERGIC SYSTEM; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CENTRAL NERVOUS SYSTEM; ENERGY EXPENDITURE; FEEDING BEHAVIOR; HINDLIMB; HUMAN; HYPERTENSION; KIDNEY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PREVALENCE; REVIEW; SIGNAL TRANSDUCTION; SYMPATHETIC NERVE; WEIGHT REDUCTION;

ANIMALS; ANTI-OBESITY AGENTS; BRAIN; DRUG RESISTANCE; HUMANS; HYPERTENSION; HYPOTHALAMUS; LEPTIN; NEUROPEPTIDE Y; OBESITY; RECEPTORS, CELL SURFACE; RECEPTORS, CORTICOTROPIN; RECEPTORS, MELANOCORTIN; RECEPTORS, NEUROPEPTIDE Y; SYMPATHETIC NERVOUS SYSTEM;

EID: 0036998936     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2002.38.12.740203     Document Type: Review

References (69)

1. Kopelman, P.G. Obesity as a medical problem. Nature 2000, 404: 635-43.
2. Hubert, H.B., Feinleib, M., McNamara, P.M., Castelli, W.P. Obesity as an independent risk factor for cardiovascular disease: A 25-year follow-up of participants in the Framingham Heart Study. Circulation 1983, 67: 968-77.
3. Kushner, R.F. Body weight and mortality. Nutr Rev 1993, 51: 127-36.
4. Stamler, R., Stamler, J., Riedlinger, W.F. et al. Weight and blood pressure. Findings in hypertension screening of 1 million Americans. JAMA 1978, 240: 1607-10.
5. Mikhail, N., Golub, M.S., Tuck, M.L. Obesity and hypertension. Prog Cardiovasc Dis 1999, 42: 39-58.
6. Rocchini, A.P., Moorhead, C.P., Deremer, S., Bondi, D. Pathogenesis of weight-related pressure changes in blood pressure in dogs. Hypertension 1989, 13: 922-8.
7. Iwashita, S., Tanida, M., Terui, N. et al. Direct measurement of renal sympathetic nervous activity in high-fat diet-related hypertensive rats. Life Sci 2002, 71: 537-46.
8. Sowers, J.R., Whitfield, L.A., Catania, R.A. et al. Role of the sympathetic nervous system in blood pressure maintenance in obesity. J Clin Endocrinol Metab 1982, 54: 1181-6.
9. Young, J.B., Landsberg, L. Diet-induced changes in sympathetic nervous system activity: Possible implications for obesity and hypertension. J Chronic Dis 1982, 35: 879-86.
10. Grassi, G., Servalle, G., Cattaneo, B.M. et al. Sympathetic activation in obese normotensive subjects. Hypertension 1995, 25: 560-3.
11. Vollenweider, P., Randin, D., Tappy, L. et al. Impaired insulin-induced sympathetic neural activation and vasodilation in skeletal muscle in obese humans. J Clin Invest 1994, 93: 2365-71.
12. Vaz, M., Jennings, G., Turner, A. et al. Regional sympathetic nervous activity and oxygen consumption in obese normotensive human subjects. Circulation 199, 96: 3423-9.
13. Rahmouni, K., Haynes, W.G., Morgan, D.A., Mark, A.L. Selective resistance to central neural administration of leptin in agouti obese mice. Hypertension 2002, 39: 486-90.
14. Morgan, D.A., Anderson, E.A., Mark, A.L. Renal sympathetic nerve activity is increased in obese Zucker rats. Hypertension 1995, 25: 834-8.
15. Hall, J.E., Hildebrandt, D.A., Kuo, J., Fitzgerald, S. Role of sympathetic nervous system and neuropeptides in obesity hypertension. Braz J Med Biol Res 2000, 33: 605-18.
16. Kassab, S., Kato, T., Wilkins, C. et al. Renal denervation attenuates the sodium retention and hypertension associated with obesity. Hypertension 1995, 25: 893-7.
17. Anderson, E.A., Mark, A.L. The vasodilator action of insulin. Implications for the insulin hypothesis of hypertension. Hypertension 1993, 21: 136-41
18. Hall, J.E. Mechanisms of abnormal renal sodium handling in obesity hypertension. Am J Hypertens 1997, 10: 49-55S.
19. Elmquist, J.K., Elias, C.F., Saper, C.B. From lesions to leptin: Hypothalamic control of food intake and body weight. Neuron 1999, 22: 221-32.
20. Zhang, Y., Proenca, R., Maffei, M. et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994, 372: 425-32.
21. Banks, W.A., Kastin, A.J., Huang, W., Jaspan, J.B., Maness, L.M. Leptin enters the brain by a saturable system independent of insulin. Peptides 1996, 17: 305-11.
22. Bjorbaek, C., Elmquist, J.K., Michl, P. et al. Expression of leptin receptor isoforms in rat brain microvessels. Endocrinology 1998, 139: 3485-91.
23. Wiesner, G., Vaz, M., Collier, G. et al. Leptin is released from the human brain: Influence of adiposity and gender. J Clin Endocrinol Metab 1999, 84: 2270-4.
24. Friedman, J.M., Halaas, J.L. Leptin and the regulation of body weight in mammals. Nature 1998, 395: 763-70.
25. Collins, S., Kuhn, C.M., Petro, A.E. et al. Role of leptin in fat regulation. Nature 1996, 380: 677.
26. Haynes, W.G., Morgan, D.A., Walsh, S.A., et al. Receptor-mediated regional sympathetic nerve activation by leptin. J Clin Invest 1997, 100: 270-8.
27. Dunbar, J.C., Hu, Y., Lu, H. Intracerebroventricular leptin increases lumbar and renal sympathetic nerve activity and blood pressure in normal rats. Diabetes. 1997, 46: 2040-3.
28. Shek, E.W., Brands, M.W., Hall, J.E. Chronic leptin infusion increases arterial pressure. Hypertension 1998, 32: 376-7.
29. Mark, A.L., Shaffer, R.A., Correia, M.L. et al. Contrasting blood pressure effects of obesity in leptin-deficient ob/ob mice and agouti yellow obese mice. J Hypertens 1999, 17: 1949-53.
30. Aizawa-Abe, M., Ogawa, Y., Masuzaki, H. et al. Pathophysiological role of leptin in obesity-related hypertension. J Clin Invest 2000, 105: 1243-52.
31. Agata, J., Masuda, A., Takada, M. et al. High plasma immunoreactive leptin level in essential hypertension. Am J Hypertens 1997, 10: 1171-4.
32. Considine, R.V., Sinha, M.K., Heiman, M.L. et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996, 334: 292-5.
33. Halaas, J.L., Boozer, C., Blair-West, J. et al. Physiological response to long-term peripheral and central leptin infusion in lean and obese mice. Proc Natl Acad Sci USA 1997, 94: 8878-83.
34. Van Heek, M., Compton, D.S., France, C.F. et al. Diet-induced obese mice develop peripheral, but not central, resistance to leptin. J Clin Invest 1997, 99: 385-90.
35. Vaisse, C., Halaas, J.L., Horvath, C.M. et al. Leptin activation of Stat3 in the hypothalamus of wild-type and ob/ob mice but not db/db mice. Nat Genet 1996, 14: 95-7.
36. El-Haschimi, K., Pierroz, D.D., Hileman, S.M. et al. Two defects contribute to hypothalamic leptin resistance in mice with diet-induced obesity. J Clin Invest 2000, 105: 1827-32.
37. Bjorbaek, C., El-Haschimi, K., Frantz, J.D., Flier, J.S. The role of SOCS-3 in leptin signaling and leptin resistance. J Biol Chem 1999, 274: 30059-65.
38. Clement, K., Vaisse, C., Lahlou, N. et al. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 1998, 392: 398-401.
39. Correia, M.L., Haynes, W.G., Rahmouni, K. et al. The concept of selective leptin resistance: Evidence from agouti yellow obese mice. Diabetes 2002, 51: 439-42.
40. Morgan, D.A., Rahmouni, K., Mark, A.L., Haynes, W.G. Selective leptin resistance during high fat diet in mice: Preservation of sympathetic activation despite attenuation of metabolic responses. Hypertension 2001, 38: 478 (Abstract).
41. Schwartz, M.W., Woods, S.C., Porte, D. Jr. et al. Central nervous system control of food intake. Nature 2000, 404: 661-71.
42. Satoh, N., Ogawa, Y., Katsuura, G. et al. The arcuate nucleus as a primary site of satiety effect of leptin in rats. Neurosci Lett 1997, 224: 149-52.
43. Dawson, R., Pelleymounter, M.A., Millard, W.J. et al. Attenuation of leptin-mediated effects by monosodium glutamate-induced arcuate nucleus damage. Am J Physiol 1997, 273: E202-6.
44. Haynes, W.G. Interaction between leptin and sympathetic nervous system in hypertension. Curr Hypertens Rep 2000, 2: 311-8.
45. Inui, A. Transgenic approach to the study of body weight regulation. Pharmacol Rev 2000, 52: 35-61.
46. Stanley, B.G., Kyrkouli, S.E., Lampert, S., Leibowitz, S.F. Neuropeptide Y chronically injected into the hypothalamus: A powerful neurochemical inducer of hyperphagia and obesity. Peptides 1986, 7: 1189-92.
47. Parker, E., Van Heek, M., Stamford, A. Neuropeptide Y receptors as targets for anti-obesity drug development: Perspective and current status. Eur J Pharmacol 2002, 440: 173-87.
48. Wilding, J.P., Gilbery, S.G., Bailey, C.J. et al. Increased neuropeptide-Y messenger ribonucleic acid (mRNA) and decreased neurotensin mRNA in the hypothalamus of the obese (ob/ob) mouse. Endocrinology 1993, 132: 1939-44.
49. Erickson, J.C., Hollopeter, G., Palmiter, R.D. Attenuation of the obesity syndrome of ob/ob mice by the loss of neuropeptide Y. Science 1996, 274: 1704-7.
50. Schwartz, M.W., Seeley, R.J., Woods, S.C. et al. Leptin increases hypothalamic pro-opiomelanocortin mRNA expression in the rostral arcuate nucleus. Diabetes 1997, 46: 2119-23.
51. Thornton, J.E., Cheung, C.C., Clifton, D.K., Steiner, R.A. Regulation of hypothalamic proopiomelanocortin mRNA by leptin in ob/ob mice. Endocrinology 1997, 138: 5063-6.
52. Mountjoy, K.G., Mortrud, M.T., Low, M.J. et al. Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain. Mol Endocrinol 1994, 8: 1298-308.
53. Huszar, D., Lynch, C.A., Fairchild-Huntress, V., et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 1997, 88: 131-41.
54. Haynes, W.G., Morgan, D.A., Djalali, A. et al. Interactions between the melanocortin system and leptin in control of sympathetic nerve traffic. Hypertension 1999, 33: 542-7.
55. Graham, M., Shutter, J.R., Sarmiento, U. et al. Overexpression of Agrt leads to obesity in transgenic mice. Nat Genet 1997, 17: 273-4.
56. Ollmann, M.M., Wilson, B.D., Yang, Y.K. et al. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science 1997, 278: 135-8.
57. Erickson, J.C., Clegg, K.E., Palmiter, R.D. Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature 1996, 381: 415-21.
58. Correia, M.L.G., Morgan, D.A., Mitchell, J.L. et al. Role of corticotrophin-releasing factor in effects of leptin on sympathetic nerve activity and arterial pressure. Hypertension 2001, 38: 384-8.
59. Farooqi, I.S., Jebb, S.A., Langmack, G. et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 1999, 341: 879-84.
60. Heymsfield, S.B., Greenberg, A.S., Fujioka, K. et al. Recombinant leptin for weight loss in obese and lean adults: A randomized, controlled, dose-escalation trial. JAMA 1999, 282: 1568-75.
61. Hukshorn, C.J., Saris, W.H., Westerterp-Plantenga, M.S. et al. Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men. J Clin Endocrinol Metab 2000, 85: 4003-9.
62. Lee, D.W., Leinung, M.C., Rozhavskaya-Arena, M., Grasso, P. Leptin and the treatment of obesity: Its current status. Eur J Pharmacol 2002, 440: 129-39.
63. Lambert, P.D., Anderson, K.D., Sleeman, M.W. et al. Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity. Proc Natl Acad Sci USA 2001, 98: 4652-7.
64. Gloaguen, I., Costa, P., Demartis, A. et al. Ciliary neurotrophic factor corrects obesity and diabetes associated with leptin deficiency and resistance. Proc Natl Acad Sci USA 1997, 94: 6456-61.
65. MacNeil, D.J., Howard, A.D., Guan, X. et al. The role of melanocortins in body weight regulation: Opportunities for the treatment of obesity. Eur J Pharmacol 2002, 440: 141-57.
66. Pierroz, D.D., Ziotopoulou, M., Ungsunan, L. et al. Effects of acute and chronic administration of the melanocortin agonist MTII in mice with diet-induced obesity. Diabetes 2002, 51: 1337-45.
67. Fehm, H.L., Smolnik, R., Kern, W. et al. The melanocortin melanocyte-stimulating hormone/ adrenocorticotropin(4-10) decreases body fat in humans. J Clin Endocrinol Metab 2001, 86: 1144-8.
68. Marsh, D.J., Hollopeter, G., Kafer, K.E., Palmiter, R.D. Role of the Y5 neuropeptide Y receptor in feeding and obesity. Nat Med 1998, 4: 718-21.
69. Turnbull, A.V., Ellershaw, L., Masters, D.J. et al. Selective antagonism of the neuropeptide Y Y5 receptor does not have a major effect on feeding in rats. Diabetes 2002, 51: 2441-9.